Not medical advice. DrPep does not sell peptides. Educational content only — many compounds are investigational or not FDA-approved. Verify against primary sources and talk with a licensed clinician.

News

Compounding · Oct 14, 2026

FDA Interim Access Policy for certain peptides sent to White House review

OIRA listing only — text not public yet.

OIRA

Research · Oct 26, 2026

JAMA Viewpoint on compounding peptides and FDA approval incentives

CSPI authors urge caution after July PCAC votes.

JAMA

Compounding · Apr 30, 2026

FDA proposes keeping semaglutide, tirzepatide, liraglutide off 503B list

Proposal stage; comments closed July 30.

FDA